The Australian Government Pharmaceutical Benefits Advisory Committee (PBAC) has invited consumers to comment on an application for subsidisation of the medicine ERLYAND, also known as apalutamide, and what it may mean for men living with prostate cancer.
 
The application is seeking Pharmaceutical Benefits Scheme (PBS) subsidisation specifically for the treatment of patients with high-risk castration-resistant prostate cancer with no distant metastases, which is defined by PSA doubling time of less than about  10 months.
 
PBAC would like to hear from Australian men living with this particular stage of prostate cancer, their carers, and family members to help inform their decision on whether to subsidise the drug.

PCFA, through its Prostate Cancer Support Group Network, is gathering comments via an open form survey to send to PBAC – exactly as provided – on behalf of Network consumers.

Question Title

* 1. Thinking about your diagnosis, how would this drug change your daily life? Please provide specific examples, based on your experience.

Question Title

* 2. How would your quality of life differ, if you could have access to this drug? Please provide examples of how things would change for you. 

Question Title

* 3. How would your connection to the world around you change if you could have access to this drug? Consider examples related to work and recreation, and your family. 

Question Title

* 4. If you have high-risk prostate cancer, what is it like to live with this high-risk disease and what is the psychological and emotional impact of knowing that your cancer may spread? How could this drug change things for you?

T